Over the last few years a number of new different compounds have been developed. They include phosphatidylinositol 3-kinase (PI3-K) inhibitors. Deregulation within the PI3-K pathway is common in head neck squamous cell carcinoma (HNSCC) and it represents a growing area of research. PI3-K inhibitors, including BKM120, PX-866 and BYL719, are being tested in several phase I and phase II studies in patients with locally advanced, recurrent or metastatic disease. This review provides an update of published clinical trials and highlights the challenges of PI3-K inhibitors in HNSCC. (C) 2017 Elsevier Ltd. All rights reserved.

New drug development in head and neck squamous cell carcinoma: the PI3-K inhibitors / DE FELICE, Francesca; Guerrero Urbano, Teresa. - In: ORAL ONCOLOGY. - ISSN 1368-8375. - STAMPA. - 67:(2017), pp. 119-123. [10.1016/j.oraloncology.2017.02.020]

New drug development in head and neck squamous cell carcinoma: the PI3-K inhibitors

DE FELICE, FRANCESCA
Primo
;
2017

Abstract

Over the last few years a number of new different compounds have been developed. They include phosphatidylinositol 3-kinase (PI3-K) inhibitors. Deregulation within the PI3-K pathway is common in head neck squamous cell carcinoma (HNSCC) and it represents a growing area of research. PI3-K inhibitors, including BKM120, PX-866 and BYL719, are being tested in several phase I and phase II studies in patients with locally advanced, recurrent or metastatic disease. This review provides an update of published clinical trials and highlights the challenges of PI3-K inhibitors in HNSCC. (C) 2017 Elsevier Ltd. All rights reserved.
2017
head and neck cancer; olcally advanced disease; PI3-K inhibitors; radiotherapy; recurrence; squamous cell; survival; oral surgery; oncology; cancer research
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
New drug development in head and neck squamous cell carcinoma: the PI3-K inhibitors / DE FELICE, Francesca; Guerrero Urbano, Teresa. - In: ORAL ONCOLOGY. - ISSN 1368-8375. - STAMPA. - 67:(2017), pp. 119-123. [10.1016/j.oraloncology.2017.02.020]
File allegati a questo prodotto
File Dimensione Formato  
De Felice_New-drug_2017.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 291.76 kB
Formato Adobe PDF
291.76 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/951990
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 18
social impact